To support the use of NT-proBNP to better detect heart failure in patients with type 2 diabetes

Endocrine. 2023 Oct;82(1):42-46. doi: 10.1007/s12020-023-03419-2. Epub 2023 Jun 20.

Abstract

Purpose: Heart failure (HF) is a chronic disease that causes approximately 300,000 and 250,000 deaths per year in Europe and United States, respectively. Type 2 Diabetes Mellitus (T2DM) is one the major risk factors of HF, and the investigation of NT-proBNP might support the early identification of HF in T2DM sufferers. Nevertheless, this parameter is poorly investigated. Thus, we aimed to demographically and clinically characterize diabetic patients which were prescribed with NT-proBNP in the primary care setting.

Methods: Using a primary care database, we formed a cohort of patients aged ≥18 years diagnosed with T2DM between 2002 and 2021. A multivariate Cox model was adopted to assess the determinants associated with the prescription of NT-proBNP.

Results: Among 167,961 T2DM patients, 7558 (4.5%, 95% CI: 4.4-4.6) were prescribed with NT-proBNP. Males and increasing age were expectedly associated with a higher propensity to be prescribed with NT-proBNP. In addition, a significant association was found for those suffering from obesity, ischemic cardiomyopathy, stroke, atrial fibrillation, hypertension, and with a Charlson Index of 2+.

Conclusion: These determinants might contribute to investigate the NT-proBNP in T2DM sufferers. A decision support system to appropriately ease the prescription of NT-proBNP might be therefore implemented in primary care settings.

MeSH terms

  • Adolescent
  • Adult
  • Biomarkers
  • Diabetes Mellitus, Type 2* / complications
  • Heart Failure* / etiology
  • Humans
  • Male
  • Natriuretic Peptide, Brain
  • Peptide Fragments
  • Prognosis

Substances

  • pro-brain natriuretic peptide (1-76)
  • Natriuretic Peptide, Brain
  • Peptide Fragments
  • Biomarkers